ProCE Banner Activity

Expert Commentary and Insight on Key Data From the 2023 ASCO Annual Meeting Informing Treatment for Endometrial, Cervical, and Ovarian Cancers

Clinical Thought

In this commentary, Kathleen Moore, MD, and Nicoletta Colombo, MD, PhD, share their thoughts on key new data for gynecologic cancers presented at the 2023 ASCO Annual Meeting, including new clinical trial results for endometrial, cervical, and ovarian cancers.

Released: June 29, 2023

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD

Associate Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Kathleen Moore

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Virginia kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase 1 Clinical Trials Unit
Professor
Department of Gynecologic Oncology
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options (CCO)

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD

Associate Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Nicoletta Colombo, MD: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Immunogen Merck Sharp & Doheme, Mersana, Nuvation, Oncxerna, Pfizer, Pieris, Roche.

Kathleen Moore, MD, MS

Associate Director, Clinical Research
Virginia kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase 1 Clinical Trials Unit
Professor
Department of Gynecologic Oncology
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma

Kathleen Moore, MD, MS: consultant/advisor/speaker: Aadi, AstraZeneca, Aravive, Alkermes, Blueprint Pharma, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Immunogen, Inxmed, Imab, Janssen, Lilly, Merck, Mereo, Mersana, Myriad, Novartis, Onconova, Oncxerna, Pannavance, Regeneron, VBL Therapeutics, Verastem, Zentalis; independent contractor: GOG Partners Associate Director.